Fast Track Group (CRNX) Q2 FY26 Earnings Call

Early Pelsonify access and prescribing momentum are positive, but launch cadence remains uncertain and spending is rising.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length60 minutes
EPS$-1.14
EPS consensus$-1.23

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

Read the full Q2 FY26 earnings call transcript

All CRNX earnings ยท Back to CRNX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.